Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Platinum agents have shown demonstrable activity in the treatment of patients with platinum resistant, recurrent ovarian cancer when delivered in a "dose-dense" fashion. However, the development of thrombocytopenia limits the weekly administration of carboplatin to no greater than AUC 2. Paclitaxel has a well-described platelet sparing effect however its use to explicitly provide thromboprotection in the context of dose dense carboplatin has not been explored. METHODS: We treated seven patients with platinum resistant ovarian cancer who had previously received paclitaxel or who had developed significant peripheral neuropathy precluding the use of further full dose weekly paclitaxel. RESULTS: We were able to deliver carboplatin AUC 3 and paclitaxel 20 mg/m2 with no thrombocytopenia or worsening of neuropathic side-effects, and with good activity. CONCLUSIONS: We conclude that this regimen may be feasible and active, and could be formally developed as a "platinum-focussed dose-dense scaffold" into which targeted therapies that reverse platinum resistance can be incorporated, and merits further evaluation.

Original publication

DOI

10.1186/1471-2407-11-289

Type

Journal article

Journal

BMC Cancer

Publication Date

11/07/2011

Volume

11

Keywords

Adenocarcinoma, Adenocarcinoma, Papillary, Aged, Aged, 80 and over, Antineoplastic Agents, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, Area Under Curve, Blood Platelets, Carboplatin, Cisplatin, Combined Modality Therapy, Cystadenocarcinoma, Serous, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Resistance, Neoplasm, Etoposide, Female, Granulosa Cell Tumor, Humans, Middle Aged, Ovarian Neoplasms, Ovariectomy, Paclitaxel, Peripheral Nervous System Diseases, Salvage Therapy, Tamoxifen, Thrombocytopenia, Treatment Outcome